{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:01:59Z","timestamp":1779951719713,"version":"3.53.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-026-05571-5","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:10:22Z","timestamp":1779948622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Review of systemic therapy in HCC with an approach to response assessment in clinical practice"],"prefix":"10.1007","author":[{"given":"Kevin A.","family":"Zand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetu","family":"Mukherji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"El Homsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Imanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amita","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charanjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"3","key":"5571_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol 2022;76 (3):681\u2013693. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018","journal-title":"J Hepatol"},{"issue":"15","key":"5571_CR2","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.23.02745","volume":"42","author":"JD Gordan","year":"2024","unstructured":"Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. J Clin Oncol 2024;42 (15):1830\u20131850. https:\/\/doi.org\/10.1200\/JCO.23.02745","journal-title":"J Clin Oncol"},{"issue":"8","key":"5571_CR3","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.1007\/s00261-021-03069-w","volume":"46","author":"JH Yacoub","year":"2021","unstructured":"Yacoub JH, Hsu CC, Fishbein TM, Mauro D, Moon A, He AR, Bashir MR, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention. Abdom Radiol (NY) 2021;46 (8):3528\u20133539. https:\/\/doi.org\/10.1007\/s00261-021-03069-w","journal-title":"Abdom Radiol (NY)"},{"issue":"8","key":"5571_CR4","doi-asserted-by":"publisher","first-page":"3540","DOI":"10.1007\/s00261-021-03074-z","volume":"46","author":"JH Yacoub","year":"2021","unstructured":"Yacoub JH, Mauro D, Moon A, He AR, Bashir MR, Hsu CC, Fishbein TM, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdom Radiol (NY) 2021;46 (8):3540\u20133548. https:\/\/doi.org\/10.1007\/s00261-021-03074-z","journal-title":"Abdom Radiol (NY)"},{"issue":"4","key":"5571_CR5","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J, Group SIS. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359 (4):378\u2013390. https:\/\/doi.org\/10.1056\/NEJMoa0708857","journal-title":"N Engl J Med"},{"issue":"10126","key":"5571_CR6","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391 (10126):1163\u20131173. https:\/\/doi.org\/10.1016\/S0140-6736(18)30207-1","journal-title":"Lancet"},{"issue":"10064","key":"5571_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G, Investigators R. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;389 (10064):56\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(16)32453-9","journal-title":"Lancet"},{"issue":"1","key":"5571_CR8","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMoa1717002","volume":"379","author":"GK Abou-Alfa","year":"2018","unstructured":"Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, Blanc JF, Bolondi L, Klumpen HJ, Chan SL, Zagonel V, Pressiani T, Ryu MH, Venook AP, Hessel C, Borgman-Hagey AE, Schwab G, Kelley RK. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 2018;379 (1):54\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1717002","journal-title":"N Engl J Med"},{"issue":"2","key":"5571_CR9","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","volume":"20","author":"AX Zhu","year":"2019","unstructured":"Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau KM, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart JB, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M, investigators R-s. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2019;20 (2):282\u2013296. https:\/\/doi.org\/10.1016\/S1470-2045(18)30937-9","journal-title":"Lancet Oncol"},{"issue":"20","key":"5571_CR10","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Xu DZ, Hernandez S, Liu J, Huang C, Mulla S, Wang Y, Lim HY, Zhu AX, Cheng AL, Investigators IM. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382 (20):1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"5571_CR11","doi-asserted-by":"publisher","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang Y-K, Van Dao T, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgu\u00e9 A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng A-L, Qin S, Galle PR, Ali S, Marcovitz M, Makowsky M, He P, Kurland JF, Negro A, Sangro B. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence 2022;1 (8). https:\/\/doi.org\/10.1056\/EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070"},{"key":"5571_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2025.03.033","author":"L Rimassa","year":"2025","unstructured":"Rimassa L, Chan SL, Sangro B, Lau G, Kudo M, Reig M, Breder V, Ryu MH, Ostapenko Y, Sukeepaisarnjaroen W, Varela M, Tougeron D, Crysler OV, Bouattour M, Van Dao T, Tam VC, Faccio A, Furuse J, Jeng LB, Kang YK, Kelley RK, Paskow MJ, Ran D, Xynos I, Kurland JF, Negro A, Abou-Alfa GK. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC. J Hepatol 2025. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.033","journal-title":"J Hepatol"},{"issue":"10492","key":"5571_CR13","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/S0140-6736(25)00403-9","volume":"405","author":"T Yau","year":"2025","unstructured":"Yau T, Galle PR, Decaens T, Sangro B, Qin S, da Fonseca LG, Karachiwala H, Blanc JF, Park JW, Gane E, Pinter M, Pena AM, Ikeda M, Tai D, Santoro A, Pizarro G, Chiu CF, Schenker M, He A, Chon HJ, Wojcik-Tomaszewska J, Verset G, Wang QQ, Stromko C, Neely J, Singh P, Jimenez Exposito MJ, Kudo M, CheckMate DWi. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 2025;405 (10492):1851\u20131864. https:\/\/doi.org\/10.1016\/S0140-6736(25)00403-9","journal-title":"Lancet"},{"key":"5571_CR14","doi-asserted-by":"publisher","first-page":"S657","DOI":"10.1016\/j.annonc.2024.08.1025","volume":"35","author":"T Decaens","year":"2024","unstructured":"Decaens T, Yau T, Kudo M, Sangro B, Qin S, Da Fonseca L, Karachiwala H, Park JW, Gane E, Pinter M, Tai DWM, Santoro A, Pizarro G, Chiu CF, Schenker M, He AR, Wang Q, Ogata T, Hreiki J, Galle PR. 965MO Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC): Expanded analyses from CheckMate 9DW. Annals of Oncology 2024;35:S657. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1025","journal-title":"Annals of Oncology"},{"issue":"5","key":"5571_CR15","first-page":"445","volume":"42","author":"J Furui","year":"1995","unstructured":"Furui J, Furukawa M, Kanematsu T. The low positive rate of serum alpha-fetoprotein levels in hepatitis C virus antibody-positive patients with hepatocellular carcinoma. Hepatogastroenterology 1995;42 (5):445\u2013449.","journal-title":"Hepatogastroenterology"},{"issue":"1","key":"5571_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s12672-025-02972-8","volume":"16","author":"H Shi","year":"2025","unstructured":"Shi H, Gao X, Liu P, Xing L, Qin Z, Pan Y. Unusual phenomenon in advanced hepatocellular carcinoma: declining alpha-fetoprotein levels despite disease progression. Discov Oncol 2025;16 (1):1169. https:\/\/doi.org\/10.1007\/s12672-025-02972-8","journal-title":"Discov Oncol"},{"issue":"9","key":"5571_CR17","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","volume":"1","author":"SV Bratman","year":"2020","unstructured":"Bratman SV, Yang SYC, Iafolla MAJ, Liu Z, Hansen AR, Bedard PL, Lheureux S, Spreafico A, Razak AA, Shchegrova S, Louie M, Billings P, Zimmermann B, Sethi H, Aleshin A, Torti D, Marsh K, Eagles J, Cirlan I, Hanna Y, Clouthier DL, Lien SC, Ohashi PS, Xu W, Siu LL, Pugh TJ. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer 2020;1 (9):873\u2013881. https:\/\/doi.org\/10.1038\/s43018-020-0096-5","journal-title":"Nat Cancer"},{"issue":"2","key":"5571_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45 (2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"5571_CR19","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0486","author":"GK Abou-Alfa","year":"2023","unstructured":"Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Dao TV, De Toni EN, Rimassa L, Breder V, Vasilyev A, Heurgue A, Tam VC, Mody K, Thungappa SC, Ostapenko Y, Yau T, Azevedo S, Varela M, Cheng AL, Qin S, Galle PR, Ali S, Gupta C, Makowsky M, Kurland JF, Negro A, Sangro B. Plain language summary of the HIMALAYA study: tremelimumab and durvalumab for unresectable hepatocellular carcinoma (liver cancer). Future Oncol 2023. https:\/\/doi.org\/10.2217\/fon-2023-0486","journal-title":"Future Oncol"},{"issue":"1","key":"5571_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30 (1):52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"issue":"6","key":"5571_CR21","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1097\/HEP.0000000000000494","volume":"78","author":"M Lim","year":"2023","unstructured":"Lim M, Muquith M, Miramontes B, Lee CJ, Espinoza M, Huang YH, Hsiehchen D. Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma. Hepatology 2023;78 (6):1755\u20131762. https:\/\/doi.org\/10.1097\/HEP.0000000000000494","journal-title":"Hepatology"},{"issue":"2","key":"5571_CR22","doi-asserted-by":"publisher","first-page":"e232408","DOI":"10.1148\/radiol.232408","volume":"313","author":"A Aslam","year":"2024","unstructured":"Aslam A, Chernyak V, Tang A, Miller FH, Bashir M, Do R, Sirlin C, Lewandowski RJ, Kim CY, Kielar AZ, Kambadakone AR, Yarmohammadi H, Kim E, Owen D, Charalel RA, Shenoy-Bhangle A, Burke LM, Mendiratta-Lala M. CT\/MRI LI-RADS 2024 Update: Treatment Response Assessment. Radiology 2024;313 (2):e232408. https:\/\/doi.org\/10.1148\/radiol.232408","journal-title":"Radiology"},{"issue":"8","key":"5571_CR23","first-page":"1546","volume":"9","author":"Y Ma","year":"2019","unstructured":"Ma Y, Wang Q, Dong Q, Zhan L, Zhang J. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy. Am J Cancer Res 2019;9 (8):1546\u20131553.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"5571_CR24","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litiere S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE, group Rw. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18 (3):e143\u2013e152. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8","journal-title":"Lancet Oncol"},{"key":"5571_CR25","doi-asserted-by":"publisher","first-page":"771887","DOI":"10.3389\/fmed.2021.771887","volume":"8","author":"DH Lee","year":"2021","unstructured":"Lee DH, Hwang S, Koh YH, Lee KH, Kim JY, Kim YJ, Yoon JH, Lee JH, Park JW. Outcome of Initial Progression During Nivolumab Treatment for Hepatocellular Carcinoma: Should We Use iRECIST? Front Med (Lausanne) 2021;8:771887. https:\/\/doi.org\/10.3389\/fmed.2021.771887","journal-title":"Front Med (Lausanne)"},{"key":"5571_CR26","doi-asserted-by":"publisher","first-page":"232470962110584","DOI":"10.1177\/23247096211058489","volume":"9","author":"Y Watanabe","year":"2021","unstructured":"Watanabe Y, Ogawa M, Tamura Y, Suda S, Kaneko M, Kumagawa M, Hirayama M, Matsumoto N, Yamamoto T, Moriyama M. A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab. J Investig Med High Impact Case Rep 2021;9:23247096211058489. https:\/\/doi.org\/10.1177\/23247096211058489","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"4","key":"5571_CR27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2169\/internalmedicine.9701-22","volume":"62","author":"R Shigefuku","year":"2023","unstructured":"Shigefuku R, Yoshikawa K, Tsukimoto M, Owa H, Tamai Y, Tameda M, Ogura S, Sugimoto R, Tanaka H, Eguchi A, Sugimoto K, Hasegawa H, Iwasa M, Nakagawa H. Hepatocellular Carcinoma Pseudoprogression Involving the Main Portal Vein, Right Ventricular Invasion, and Exacerbation of Lung Metastases in a Patient on Atezolizumab Plus Bevacizumab. Intern Med 2023;62 (4):539\u2013543. https:\/\/doi.org\/10.2169\/internalmedicine.9701-22","journal-title":"Intern Med"},{"issue":"3","key":"5571_CR28","doi-asserted-by":"publisher","first-page":"e211136","DOI":"10.1001\/jamanetworkopen.2021.1136","volume":"4","author":"HJ Park","year":"2021","unstructured":"Park HJ, Kim KW, Won SE, Yoon S, Chae YK, Tirumani SH, Ramaiya NH. Definition, Incidence, and Challenges for Assessment of Hyperprogressive Disease During Cancer Treatment With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4 (3):e211136. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.1136","journal-title":"JAMA Netw Open"},{"key":"5571_CR29","doi-asserted-by":"publisher","first-page":"232470962199220","DOI":"10.1177\/2324709621992207","volume":"9","author":"B Singh","year":"2021","unstructured":"Singh B, Kaur P, Maroules M. Hyperprogression in a Patient With Hepatocellular Cancer Treated With Atezolizumab and Bevacizumab: A Case Report and Review of Literature. J Investig Med High Impact Case Rep 2021;9:2324709621992207. https:\/\/doi.org\/10.1177\/2324709621992207","journal-title":"J Investig Med High Impact Case Rep"},{"issue":"2","key":"5571_CR30","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1148\/radiol.2015150667","volume":"279","author":"JF Geschwind","year":"2016","unstructured":"Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladron de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R. TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. Radiology 2016;279 (2):630\u2013640. https:\/\/doi.org\/10.1148\/radiol.2015150667","journal-title":"Radiology"},{"issue":"8","key":"5571_CR31","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y, group Ts. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 2020;69 (8):1492\u20131501. https:\/\/doi.org\/10.1136\/gutjnl-2019-318934","journal-title":"Gut"},{"issue":"10474","key":"5571_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, Qin S, Ren Z, Chan SL, Arai Y, Heo J, Mai A, Escobar J, Lopez Chuken YA, Yoon JH, Tak WY, Breder VV, Suttichaimongkol T, Bouattour M, Lin SM, Peron JM, Nguyen QT, Yan L, Chiu CF, Santos FA, Veluvolu A, Thungappa SC, Matos M, Zotkiewicz M, Udoye SI, Kurland JF, Cohen GJ, Lencioni R, Investigators E-. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2025;405 (10474):216\u2013232. https:\/\/doi.org\/10.1016\/S0140-6736(24)02551-0","journal-title":"Lancet"},{"issue":"10474","key":"5571_CR33","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM, investigators L-. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet 2025;405 (10474):203\u2013215. https:\/\/doi.org\/10.1016\/S0140-6736(24)02575-3","journal-title":"Lancet"},{"issue":"6","key":"5571_CR34","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovic P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol 2019;71 (6):1164\u20131174. https:\/\/doi.org\/10.1016\/j.jhep.2019.08.006","journal-title":"J Hepatol"},{"issue":"3","key":"5571_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.dld.2021.06.003","volume":"54","author":"A Facciorusso","year":"2022","unstructured":"Facciorusso A, Paolillo R, Tartaglia N, Ramai D, Mohan BP, Cotsoglou C, Chandan S, Ambrosi A, Bargellini I, Renzulli M, Sacco R. Efficacy of combined transarterial radioembolization and sorafenib in the treatment of hepatocarcinoma: A meta-analysis. Dig Liver Dis 2022;54 (3):316\u2013323. https:\/\/doi.org\/10.1016\/j.dld.2021.06.003","journal-title":"Dig Liver Dis"},{"issue":"12","key":"5571_CR36","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.14309\/ajg.0000000000002467","volume":"118","author":"YH Yeo","year":"2023","unstructured":"Yeo YH, Liang J, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sankar K, Gong J, Hendifar A, Osipov A, Friedman ML, Lipshutz HG, Steinberger J, Kosari K, Nissen N, Abou-Alfa GK, Singal AG, Yang JD. Immunotherapy and Transarterial Radioembolization Combination Treatment for Advanced Hepatocellular Carcinoma. Am J Gastroenterol 2023;118 (12):2201\u20132211. https:\/\/doi.org\/10.14309\/ajg.0000000000002467","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"5571_CR37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S2468-1253","volume":"6","author":"D Tai","year":"2021","unstructured":"Tai D, Loke K, Gogna A, Kaya NA, Tan SH, Hennedige T, Ng D, Irani F, Lee J, Lim JQ, Too CW, Ng MCH, Tham CK, Lam J, Koo SL, Chong HS, Goh GB, Huang HL, Venkatanarasimha N, Lo R, Chow PKH, Goh BKP, Chung A, Toh HC, Thng CH, Lim TKH, Yeong J, Zhai W, Chan CY, Choo SP. Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): a single arm, single centre, phase 2 trial. Lancet Gastroenterol Hepatol 2021;6 (12):1025\u20131035. https:\/\/doi.org\/10.1016\/S2468-1253 (21)00305-8","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"5571_CR38","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/oncolo\/oyad331","volume":"29","author":"S Yu","year":"2024","unstructured":"Yu S, Yu M, Keane B, Mauro DM, Helft PR, Harris WP, Sanoff HK, Johnson MS, O\u2019Neil B, McRee AJ, Somasundaram A. A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma. Oncologist 2024;29 (3):270\u2013e413. https:\/\/doi.org\/10.1093\/oncolo\/oyad331","journal-title":"Oncologist"},{"issue":"5","key":"5571_CR39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.21037\/cco-24-27","volume":"13","author":"R Chen","year":"2024","unstructured":"Chen R, Monaco G, Stefanini B, Marseglia M, De Lorenzo S, Tovoli F. Combination makes strength: a narrative review of transarterial radioembolization plus immune checkpoint inhibitors for hepatocellular carcinoma. Chin Clin Oncol 2024;13 (5):71. https:\/\/doi.org\/10.21037\/cco-24-27","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"5571_CR40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1001\/jamaoncol.2024.5403","volume":"11","author":"LA Dawson","year":"2025","unstructured":"Dawson LA, Winter KA, Knox JJ, Zhu AX, Krishnan S, Guha C, Kachnic LA, Gillin MT, Hong TS, Craig TD, Williams TM, Hosni A, Chen E, Noonan AM, Koay EJ, Sinha R, Lock MI, Ohri N, Dorth JA, Delouya G, Swaminath A, Moughan J, Crane CH. Stereotactic Body Radiotherapy vs Sorafenib Alone in Hepatocellular Carcinoma: The NRG Oncology\/RTOG 1112 Phase 3 Randomized Clinical Trial. JAMA Oncol 2025;11 (2):136\u2013144. https:\/\/doi.org\/10.1001\/jamaoncol.2024.5403","journal-title":"JAMA Oncol"},{"issue":"1","key":"5571_CR41","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijrobp.2022.09.052","volume":"115","author":"A Juloori","year":"2023","unstructured":"Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, Fung J, Pillai A, Liao CY, Sharma M, Liauw SL. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced\/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 2023;115 (1):202\u2013213. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.09.052","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"5571_CR42","doi-asserted-by":"publisher","first-page":"e922","DOI":"10.1093\/oncolo\/oyae048","volume":"29","author":"CW Su","year":"2024","unstructured":"Su CW, Teng W, Shen EY, Huang BS, Lin PT, Hou MM, Wu TH, Tsan DL, Hsieh CH, Wang CT, Chai PM, Lin CY, Lin SM, Lin CC. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma. Oncologist 2024;29 (7):e922\u2013e931. https:\/\/doi.org\/10.1093\/oncolo\/oyae048","journal-title":"Oncologist"},{"issue":"4","key":"5571_CR43","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76 (4):862\u2013873. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.030","journal-title":"J Hepatol"},{"issue":"4","key":"5571_CR44","first-page":"257","volume":"8","author":"P Mehra","year":"2022","unstructured":"Mehra P, Kataria T, Gupta D, Krishan S. An observational study on tumour response of portal vein tumour thrombus in hepatocellular carcinoma. J Radiosurg SBRT 2022;8 (4):257\u2013264.","journal-title":"J Radiosurg SBRT"},{"key":"5571_CR45","unstructured":"Liver Imaging Reporting and Data System (LI-RADS\u00ae) CT\/MRI Nonradiation and Radiation TRA v2024 Core. https:\/\/www.acr.org\/Clinical-Resources\/Clinical-Tools-and-Reference\/Reporting-and-Data-Systems\/LI-RADS."},{"issue":"7","key":"5571_CR46","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1007\/s00330-016-4670-2","volume":"27","author":"BB Chen","year":"2017","unstructured":"Chen BB, Hsu CY, Yu CW, Liang PC, Hsu C, Hsu CH, Cheng AL, Shih TT. Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma. Eur Radiol 2017;27 (7):3069\u20133079. https:\/\/doi.org\/10.1007\/s00330-016-4670-2","journal-title":"Eur Radiol"},{"issue":"1","key":"5571_CR47","doi-asserted-by":"publisher","first-page":"34782","DOI":"10.1038\/s41598-025-18586-7","volume":"15","author":"J Liu","year":"2025","unstructured":"Liu J, Zhao N, Hang Y, You Q, Tian Y, Shao H. Predicting the outcome of transarterial chemoembolization combined with targeted immunotherapy for unresectable hepatocellular carcinoma based on MRI radiomics. Sci Rep 2025;15 (1):34782. https:\/\/doi.org\/10.1038\/s41598-025-18586-7","journal-title":"Sci Rep"},{"key":"5571_CR48","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.70048","author":"F Che","year":"2025","unstructured":"Che F, Zhu J, Li Q, Jiang H, Wei Y, Song B. Emerging Role of MRI-Based Artificial Intelligence in Individualized Treatment Strategies for Hepatocellular Carcinoma: A Narrative Review. J Magn Reson Imaging 2025. https:\/\/doi.org\/10.1002\/jmri.70048","journal-title":"J Magn Reson Imaging"},{"key":"5571_CR49","doi-asserted-by":"publisher","first-page":"1151967","DOI":"10.3389\/fimmu.2023.1151967","volume":"14","author":"G Wang","year":"2023","unstructured":"Wang G, Zhang W, Luan X, Wang Z, Liu J, Xu X, Zhang J, Xu B, Lu S, Wang R, Ma G. The role of (18)F-FDG PET in predicting the pathological response and prognosis to unresectable HCC patients treated with lenvatinib and PD-1 inhibitors as a conversion therapy. Front Immunol 2023;14:1151967. https:\/\/doi.org\/10.3389\/fimmu.2023.1151967","journal-title":"Front Immunol"},{"issue":"10","key":"5571_CR50","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.2967\/jnumed.123.265712","volume":"64","author":"M Wu","year":"2023","unstructured":"Wu M, Wang Y, Yang Q, Wang X, Yang X, Xing H, Sang X, Li X, Zhao H, Huo L. Comparison of Baseline (68)Ga-FAPI and (18)F-FDG PET\/CT for Prediction of Response and Clinical Outcome in Patients with Unresectable Hepatocellular Carcinoma Treated with PD-1 Inhibitor and Lenvatinib. J Nucl Med 2023;64 (10):1532\u20131539. https:\/\/doi.org\/10.2967\/jnumed.123.265712","journal-title":"J Nucl Med"},{"key":"5571_CR51","doi-asserted-by":"publisher","first-page":"587","DOI":"10.2147\/JHC.S401647","volume":"10","author":"X Wang","year":"2023","unstructured":"Wang X, Yang X, Wang J, Dong C, Ding J, Wu M, Wang Y, Ding H, Zhang H, Sang X, Zhao H, Huo L. Metabolic Tumor Volume Measured by (18)F-FDG PET\/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1\/PD-L1 Inhibitors Plus Molecular Targeted Agents. J Hepatocell Carcinoma 2023;10:587\u2013598. https:\/\/doi.org\/10.2147\/JHC.S401647","journal-title":"J Hepatocell Carcinoma"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05571-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05571-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05571-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:10:27Z","timestamp":1779948627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05571-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":51,"alternative-id":["5571"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05571-5","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}